Vascular Graft Occlusion

Obstruction of flow in biological or prosthetic vascular grafts.

Also Known As:

Graft Occlusion, Vascular; Graft Restenoses, Vascular; Occlusion, Vascular Graft; Restenosis, Vascular Graft; Graft Restenosis, Vascular; Vascular Graft Restenosis

Networked: 10 relevant articles (0 outcomes, 2 trials/studies)

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Postoperative Complications
    - Vascular Graft Occlusion: 10

Related Diseases

1.	Thrombosis (Thrombus)
2.	Thromboembolism
3.	Paralysis (Palsy)
4.	Myocardial Infarction
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease)

Experts

1.	Yuan, Shi-Min: 1 article (09/2020)
2.	Alfardan, Zuhair: 1 article (08/2011)
3.	Chhina, Tejinder: 1 article (08/2011)
4.	Hare, Gregory M T: 1 article (08/2011)
5.	Jackson, Zane S: 1 article (08/2011)
6.	Lapierre, Harry: 1 article (08/2011)
7.	Latter, David: 1 article (08/2011)
8.	Leong-Poi, Howard: 1 article (08/2011)
9.	Mahoney, James: 1 article (08/2011)
10.	Mazer, C David: 1 article (08/2011)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vascular Graft Occlusion:

1.	Polyethylene Terephthalates (Polyethylene Terephthalate)IBA 12/01/1995 - "In this sheep animal study, each of SH and two LMWH dose regimens resulted in a reduction in Dacron vascular graft occlusion rate and the development of IH, with the greatest effect seen in the low dose LMWH group."
2.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 12/01/1995 - "In this sheep animal study, each of SH and two LMWH dose regimens resulted in a reduction in Dacron vascular graft occlusion rate and the development of IH, with the greatest effect seen in the low dose LMWH group."
3.	recombinant FVIIa (rFVIIa)FDA Link 08/01/2011 - "This study suggests that recombinant factor VIIa is associated with a dose-dependent increase in fresh vascular graft occlusion. " 08/01/2011 - "However, the potential for recombinant factor VIIa to cause early vascular graft occlusion at the site of new vascular anastomoses has not been fully explored. "
4.	Proteins (Proteins, Gene)FDA Link 05/01/1988 - "Continuous intravenous infusion of FPRCH2Cl (100 nmol/kg per min) into vascular graft-bearing baboons (Papio anubis) abolished (i) vascular graft 111In-platelet deposition, (ii) vascular graft occlusion, (iii) thrombus-associated in vivo release of platelet-specific proteins and fibrinopeptides, (iv) platelet hemostatic plug formation, (v) thrombin-induced platelet aggregation ex vivo, and (vi) thrombin-induced blood clotting. " 01/01/1999 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. " 10/01/1998 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. "
5.	Thrombin FDA Link 01/22/2009 - "Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI." 05/01/1988 - "Continuous intravenous infusion of FPRCH2Cl (100 nmol/kg per min) into vascular graft-bearing baboons (Papio anubis) abolished (i) vascular graft 111In-platelet deposition, (ii) vascular graft occlusion, (iii) thrombus-associated in vivo release of platelet-specific proteins and fibrinopeptides, (iv) platelet hemostatic plug formation, (v) thrombin-induced platelet aggregation ex vivo, and (vi) thrombin-induced blood clotting. "
6.	LigandsIBA 01/01/1999 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. " 10/01/1998 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. "
7.	Biocompatible Materials (Biomaterials)IBA 01/01/1999 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. " 10/01/1998 - "For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. "
8.	IsoenzymesIBA 09/01/1993 - "Data collection included serial physical examinations, electrocardiograms, and cardiac isoenzymes to detect arterial thrombosis (defined as unstable angina, myocardial infarction, or vascular graft occlusion requiring reoperation). "
9.	Hemostatics (Antihemorrhagics)IBA 05/01/1988 - "Continuous intravenous infusion of FPRCH2Cl (100 nmol/kg per min) into vascular graft-bearing baboons (Papio anubis) abolished (i) vascular graft 111In-platelet deposition, (ii) vascular graft occlusion, (iii) thrombus-associated in vivo release of platelet-specific proteins and fibrinopeptides, (iv) platelet hemostatic plug formation, (v) thrombin-induced platelet aggregation ex vivo, and (vi) thrombin-induced blood clotting. "
10.	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/22/2009 - "Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI."

Therapies and Procedures

1.	Hip Replacement Arthroplasty (Total Hip Replacement) 01/01/2011 - "Sciatic palsy after total hip arthroplasty associated with vascular graft occlusion."
2.	Vascular Surgical Procedures 01/01/1985 - "Differentiation is often difficult between vascular graft occlusion and progression of underlying disease in patients after vascular surgery. "
3.	Intravenous Infusions 05/01/1988 - "Continuous intravenous infusion of FPRCH2Cl (100 nmol/kg per min) into vascular graft-bearing baboons (Papio anubis) abolished (i) vascular graft 111In-platelet deposition, (ii) vascular graft occlusion, (iii) thrombus-associated in vivo release of platelet-specific proteins and fibrinopeptides, (iv) platelet hemostatic plug formation, (v) thrombin-induced platelet aggregation ex vivo, and (vi) thrombin-induced blood clotting. "
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 09/01/2020 - "Key Words: Coronary artery bypass grafting, Graft occlusion, Vascular, Systemic lupus erythematosus."